These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 25927594)

  • 1. Recombinant B domain deleted porcine factor VIII for the treatment of bleeding episodes in adults with acquired hemophilia A.
    Gomperts E
    Expert Rev Hematol; 2015 Aug; 8(4):427-32. PubMed ID: 25927594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant B-domain-deleted porcine sequence factor VIII (r-pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors.
    Mahlangu JN; Andreeva TA; Macfarlane DE; Walsh C; Key NS
    Haemophilia; 2017 Jan; 23(1):33-41. PubMed ID: 27761964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of recombinant porcine factor VIII in Japanese patients with acquired hemophilia A.
    Seki Y; Ogawa Y; Kikuchi T; Sakaida E; Mizuta Y; Kitagawa T; Takemura K; Miyaguchi Y; Nogami K; Matsushita T
    Int J Hematol; 2024 Oct; 120(4):482-491. PubMed ID: 39158833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant porcine factor VIII for high-risk surgery in paediatric congenital haemophilia A with high-titre inhibitor.
    Croteau SE; Abajas YL; Wolberg AS; Nielsen BI; Marx GR; Baird CW; Neufeld EJ; Monahan PE
    Haemophilia; 2017 Mar; 23(2):e93-e98. PubMed ID: 28124406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susoctocog Alfa: A Review in Acquired Haemophilia A.
    Burness CB; Scott LJ
    Drugs; 2016 May; 76(7):815-21. PubMed ID: 27098420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A.
    Kruse-Jarres R; St-Louis J; Greist A; Shapiro A; Smith H; Chowdary P; Drebes A; Gomperts E; Bourgeois C; Mo M; Novack A; Farin H; Ewenstein B
    Haemophilia; 2015 Mar; 21(2):162-170. PubMed ID: 25623166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OBI-1, porcine recombinant Factor VIII for the potential treatment of patients with congenital hemophilia A and alloantibodies against human Factor VIII.
    Toschi V
    Curr Opin Mol Ther; 2010 Oct; 12(5):617-25. PubMed ID: 20886394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients.
    Tarantino MD; Cuker A; Hardesty B; Roberts JC; Sholzberg M
    Haemophilia; 2017 Jan; 23(1):25-32. PubMed ID: 27511890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profile.
    Lillicrap D; Schiviz A; Apostol C; Wojciechowski P; Horling F; Lai CK; Piskernik C; Hoellriegl W; Lollar P
    Haemophilia; 2016 Mar; 22(2):308-317. PubMed ID: 26278557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short term efficacy of recombinant porcine factor VIII in patients with factor VIII inhibitors.
    Abou-Ismail MY; Vuyyala S; Prunty J; Schmaier AH; Nayak L
    Haemophilia; 2020 Jul; 26(4):601-606. PubMed ID: 32338423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of recombinant anti-haemophilic porcine sequence factor VIII in adults with acquired haemophilia A.
    Fosbury E; Drebes A; Riddell A; Chowdary P
    Ther Adv Hematol; 2017 Sep; 8(9):263-272. PubMed ID: 29051804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Porcine recombinant factor VIII: an additional weapon to handle anti-factor VIII antibodies.
    Mannucci PM; Franchini M
    Blood Transfus; 2017 Jul; 15(4):365-368. PubMed ID: 27483484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study.
    Kim SK; Yoo KY; Lee KS; Hwang T; Choi YM; Choi EJ; Park SK
    J Korean Med Sci; 2018 Jan; 33(1):e5. PubMed ID: 29215814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Turoctocog alfa for the treatment of hemophilia A.
    Haddley K
    Drugs Today (Barc); 2014 Feb; 50(2):121-31. PubMed ID: 24619589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Turoctocog alfa for the treatment of hemophilia a.
    Vakil NH; Fujinami N; Martin-Stone S
    Pharmacotherapy; 2014 Oct; 34(10):1091-101. PubMed ID: 25052207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa).
    Franchini M; Mannucci PM
    Expert Opin Drug Saf; 2017 Mar; 16(3):405-410. PubMed ID: 28103444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant porcine FVIII for bleed treatment in acquired hemophilia A: findings from a single-center, 18-patient cohort.
    Ellsworth P; Chen SL; Kasthuri RS; Key NS; Mooberry MJ; Ma AD
    Blood Adv; 2020 Dec; 4(24):6240-6249. PubMed ID: 33351122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging drugs for hemophilia A: insights into phase II and III clinical trials.
    Kizilocak H; Young G
    Expert Opin Emerg Drugs; 2021 Dec; 26(4):337-350. PubMed ID: 34601977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant porcine factor VIII in patients with congenital haemophilia A with inhibitors undergoing surgery: Phase 3, single-arm, open-label study.
    Pfrepper C; Radossi P; Windyga J; Kavakli K; Schutgens R; Sarper N; Gu J; Badejo K; Jain N
    Haemophilia; 2024 Mar; 30(2):395-403. PubMed ID: 38317504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo studies of activated porcine factor VIII.
    Littlewood JD; Bevan SA; Kemball-Cook G; Barrowcliffe TW
    Thromb Haemost; 1996 Nov; 76(5):743-8. PubMed ID: 8950784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.